Lipoprotein X in a patient with cholestasis and hypertriglyceridaemia

Annals of Clinical Biochemistry

Volumn 50, Issue 2, 2013, Pages 173-175

  Stepien, Karolina M ^a   Divyateja, Hrushikesh ^a   Ahmed, Farhan ^a   Prinsloo, Peter ^a   Gupta, Pankaj ^a  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; APOLIPOPROTEIN B; ATORVASTATIN; BILIRUBIN; CHOLESTEROL; FENOFIBRATE; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; INSULIN ASPART; INSULIN GLARGINE; LANTUS SOLOSTAR; LIPOPROTEIN X; METFORMIN; STEROID; TESTOSTERONE; THYROTROPIN; TRIACYLGLYCEROL; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; BODY MASS; CASE REPORT; CHOLECYSTECTOMY; CHOLESTASIS; CHOLESTEROL BLOOD LEVEL; CHRONIC PANCREATITIS; CLINICAL FEATURE; DISEASE ASSOCIATION; DRINKING BEHAVIOR; DRUG SELF ADMINISTRATION; DRUG WITHDRAWAL; ELECTROPHORESIS; EVENING DOSAGE; FOLLOW UP; GALLSTONE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEPATOMEGALY; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HUMAN TISSUE; HYPERTRIGLYCERIDEMIA; JAUNDICE; LIPOPROTEIN BLOOD LEVEL; LIVER BIOPSY; LIVER FUNCTION TEST; LOW FAT DIET; MALE; MEDICAL HISTORY; MUSCLE STRENGTH; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OUTPATIENT; PANCREAS SURGERY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RASH; SIDE EFFECT; SURGICAL WARD; THYROTROPIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; TRIACYLGLYCEROL LIPASE BLOOD LEVEL; WEIGHT REDUCTION; XANTHOMA;

ADULT; CHOLESTASIS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN-X; MALE;

EID: 84879439438     PISSN: 00045632     EISSN: 17581001     Source Type: Journal    
DOI: 10.1258/acb.2012.012148     Document Type: Article

References (23)

1. Gan SI, Edwards AL, Symonds CJ, et al. Hypertriglyceridemia-induced pancreatitis: a case-based review. World J Gastroenterol 2006;12:7197-202
2. Young SP, Thompson JP. Severe acute pancreatitis. Contin Educ Anesth Critic Care Pain 2008;8:125-8
3. Fung MA, Frohlich JJ. Common problems in the management of hypertriglyceridemia. Can Med Assoc J 2002;167:1261-6
4. Alen M, Rahkila P. Anabolic-androgenic steroid effects on endocrinology and lipid metabolism in athletes. Sports Med 1988;6:327-32
5. Morikawa AT, Maranhao RC, Alves MJNN, Negrao CE, da Silva JL, Vinagre GC. Effects of anabolic androgenic steroids on chylomicron metabolism. Steroids 2012, http://www.sciencedirect.com/science/ article/pii/S0039128X12002218
6. Scott J, Summerfield JA, Elias E, et al. Chronic pancreatitis: a cause of cholestasis. Gut 1977;18:196-201
7. Ho CY, Kuo TH, Chen TS, et al. Fenofibrate-induced acute cholestatic hepatitis. J Chin Med Assoc 2004;67:245-7
8. Switzer S. Plasma lipoproteins in liver disease: I. Immunologicallydistinct low-density lipoproteins in patients with biliary obstruction. J Clin Invest 1967;46:1855-66
9. Narayan S. Biochemistry and the clinical relevance of lipoprotein X. Ann Clin Lab Sci 1984;14:371-4
10. Glickman RM, Sabesin SM. Lipoprotein metabolism. In: Arias IM, Boyer JL, eds. The Liver: Biology and Pathobiology. New York: Raven, 1994:391-414
11. Sneidel D, Alaupovic R, Furman RH, et al. A lipoprotein characterising obstructive jaundice. II. Isolation and partial characterisation of the protein moieties of low-density lipoproteins. J Clin Invest 1970;49:2396-407
12. Seidel D, Alaupovic P, Furman RH. A lipoprotein characterising obstructive jaundice. I. A method for quantitative separation and identification of lipoproteins in jaundiced subjects. J Clin Invest 1969;48:1211-23
13. Seidel D, Alaupovic P, Furman RH. A lipoprotein characterising obstructive jaundice. I. A method for the quantitative separation and identification of lipoproteins in jaundiced subjects. J Clin Invest 1967;46:1211
14. Neubeck W, Seidel D. A direct method for measuring lipoprotein X in serum. Clin Chem 1975;21:853-6
15. Ritland S, Gjone E. Quantitative studies of lipoprotein X in familial lecithin cholesterol acyltransferase deficiency and during cholesterol estrification. Clin Chim Acta 1975;59:109-19
16. Steinberg D, Witztum JL. Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation 2002;105:2107-11
17. Chang P-Y, Lu S-C, Su T-C, et al. Lipoprotein X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation. J Lipid Res 2004;45:2116-22
18. Utermann G, Schoenborn W, Langer KH, et al. Lipoproteins in LCAT-deficiency. Humangenetik 1972;16:295
19. Wemmer U, Spelger G. The diagnosis of cholestasis in acute viral hepatitis in childhood. Klin Padiatr 1980;192:249-53
20. Suehira S, Baba T, Ichimura M, et al. A case of drug-induced hepatitis with the hyperlipoprotein-X-emia and densitometric determination of lipoprotein-X in the patient's serum after agarose gel electrophoresis and enzymatic cholesterol staining. Japan J Clin Pathol 1984;32:1365-71
21. Manukyan L, Boyajyan A, Arakelyan A, et al. The immunochemical composition of cryoglobulins generated in stroke. J Clin Immunol 2009;29:274-81
22. Dimeski G, Mollee P, Carter A. Effects of hyperlipidemia on plasma sodium, potassium, and chloride measurements by an indirect ion-selective electrode measuring system. Clin Chem 2006;52:155-6
23. Sivakumar T, Chaidarun S, Lee HK, Cervinski M, Comi R. Multiple lipoprotein and electrolyte laboratory artifacts caused by lipoprotein X in obstructive biliary cholestasis secondary to pancreatic cancer. J Clin Lipidol 2011;5:324-328